GlassScriptPhysician profile
Alberto Arias
NPI 1730616079
$1,442.08
in general payments reported to CMS, 2019-2025
21 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.58 · 2021: $331 · 2022: $420 · 2023: $360 · 2024: $163 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $293.14 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $138.21 | 2023-2024 | Vraylar, Ubrelvy |
| Abbott Laboratories | $129.93 | 2021-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $98.33 | 2020-2025 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $97.10 | 2021 | |
| Lilly USA, LLC | $73.49 | 2022-2024 | Mounjaro, Trulicity |
| Exact Sciences Corporation | $69.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $68.47 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $57.28 | 2022-2023 | Rexulti |
| Glaxosmithkline, LLC. | $56.75 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $55.69 | 2022 | |
| Boston Scientific Corporation | $48.34 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Sanofi-Aventis U.S. LLC | $43.11 | 2021 | |
| Pfizer INC. | $39.50 | 2023 | |
| Janssen Pharmaceuticals, INC | $38.75 | 2023 | Spravato |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.73 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.80 | 2021 | |
| Chiesi USA, INC. | $23.54 | 2024 | Myalept |
| Amgen INC. | $15.11 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.52 | 2021 | |
| Esperion Therapeutics, INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Arias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.